Three-question Skindex-Mini measures quality of life in children with atopic dermatitis

Sheth, Anjani; Blumstein, Alli J.; Rangel, Stephanie M.; Jackson, Kathryn; Lai, Jin‐Shei; Paller, Amy S.

doi:10.1016/j.jaad.2022.06.1167

Cited by 4 publications

(7 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In total, 12 articles reporting on 12 different PROMs in 45 single studies on measurement properties were analyzed 18,26,28–37 …”

Section: Resultsmentioning

confidence: 99%

“…This was followed by deduplication (removing duplicates) using the reference management software Citavi 6 (https://www.citavi.com/de/download). An additional study that was published after the systematic literature search was brought to our attention at a conference 18 . This systematic review update was not registered.…”

Section: Methodsmentioning

confidence: 99%

“…In total, 12 articles reporting on 12 different PROMs in 45 single studies on measurement properties were analyzed. 18,26,[28][29][30][31][32][33][34][35][36][37] Relevant characteristics of the identified PROMs, such as number of items, recall period, response categories, and target population., are presented in Appendix S3. Relevant characteristics of the included study populations can be found in Appendix S4.…”

Section: Data Extractionmentioning

confidence: 99%

“…38 The three-item Skindex-Mini was recently validated in children with AE. 18 The summary of findings of the assessed PROMs for infants and children with AE is presented in Table 1. The new evidence since 2019 is highlighted in blue.…”

Section: Summary Of Findings-infants and Childrenmentioning

confidence: 99%

See 3 more Smart Citations

Measurement properties of quality‐of‐life outcome measures for children and adults with eczema: A systematic review update 2.0

Gabes

Donhauser

Piontek

et al. 2023

Pediatric Allergy Immunology

View full text Add to dashboard Cite

A systematic review on measurement properties of patient-reported outcome measures (PROMs) for the assessment of quality of life (QoL) in children and adults with eczema was published in 2016 and updated in 2019. We now aimed to systematically assess the measurement properties of PROMs based on recently published development and validation studies regarding quality-of-life skin-or disease-specific PROMs using the COnsensus-based Standards for the selection of health Measurement Instruments (COSMIN) guidelines and integrate these findings with those from the 2019 update. A systematic literature search was conducted in PubMed and Embase.Eligible studies reported on measurement properties of QoL skin-or disease-specific PROMs for the assessment of QoL in children and adults with eczema. The methodological quality of the included studies was evaluated using the COSMIN Risk of Bias checklist. The methodological quality of the included PROMs was judged using updated criteria for good measurement properties, and the quality of evidence was graded. The new evidence was integrated into the results from the 2019 update. Finally, a recommendation for use of the identified PROMs was derived based on all evidence.We identified 12 studies fulfilling our inclusion criteria. Based on the newly generated evidence, the Childhood Atopic Dermatitis Impact Scale-short form (CADIS-SF) for infants and the Skindex for adults can be recommended for use. We identified three new PROMs, which have the potential to be used, but require further validation: the Pediatric Allergic Disease Quality of Life Questionnaire (PADQLQ), the Skindex-Mini,

show abstract

“…In total, 12 articles reporting on 12 different PROMs in 45 single studies on measurement properties were analyzed 18,26,28–37 …”

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Data Extractionmentioning

confidence: 99%

Section: Summary Of Findings-infants and Childrenmentioning

confidence: 99%

See 2 more Smart Citations

Measurement properties of quality‐of‐life outcome measures for children and adults with eczema: A systematic review update 2.0

Gabes

Donhauser

Piontek

et al. 2023

Pediatric Allergy Immunology

View full text Add to dashboard Cite

show abstract

“…It is therefore important for physicians to discuss the impact of AD on QoL with patients and base their perceptions on individual patient feedback rather than on their assumptions based on an “average” patient with AD. Brief, easy-to-use patient-reported outcome tools can be used to make an assessment during consultations, including the Children’s Dermatology Life Quality Index (CDLQI) [ 37 ] or Skindex-Mini [ 38 , 39 ] for QoL, POEM [ 27 ] for symptoms, and Atopic Dermatitis Control Tool (ADCT) for symptoms and impact of AD on patients’ everyday lives and well-being [ 40 ]. These assessments should be done periodically, as QoL concerns can change as the child matures.…”

Section: Discussionmentioning

confidence: 99%

Similarities and Differences in the Perception of Atopic Dermatitis Burden Between Patients, Caregivers, and Independent Physicians (AD-GAP Survey)

Paller

Weidinger

Capozza

et al. 2023

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

Introduction Atopic dermatitis (AD)—a chronic inflammatory skin disease characterized by intense itching—can have a detrimental impact on quality of life (QoL). We report results of a quantitative assessment of pediatric patient, caregiver, and physician perceptions of AD burden in children and adolescents. Methods Pediatric patients (aged 6–11 [children] or 12–17 [adolescents] years) with moderate-to-severe AD, their caregivers, and independent physicians were recruited in 13 countries. Caregivers and their children/adolescents completed an online survey about the impact of AD on 16 key items of patient QoL. Physicians completed surveys on their patients aged 6–11 and 12–17 years. Best–worst scaling was used to rank the importance of the QoL items. Results Overall, 1447 children/adolescents with moderate-to-severe AD (aged 6–11 years: 701; 12–17 years: 746), 1447 caregivers, and 1092 physicians participated. Patients and caregivers in both age groups ranked disturbed sleep as the most important QoL item, followed by feeling ashamed because of AD. Independent physicians ranked feeling ashamed because of AD as the most important QoL item for both age groups, followed by disturbed sleep for those aged 6–11 years and being singled out for those aged 12–17 years. The relative importance of the 16 QoL items to patients was strongly aligned between patients in both age groups and their caregivers, but somewhat less so between patients and physicians. Between-country differences were more apparent in physician- versus patient-/caregiver-reported results. Conclusion The most burdensome QoL items were impact of AD on sleep and feeling ashamed. Caregivers and physicians correctly identified the QoL items most burdensome to patients. However, patient and caregiver perceptions were generally more closely aligned than patient and physician perceptions. Between-country differences in perceptions (particularly for physicians) were observed, probably due to multifactorial reasons, necessitating further evaluation. Infographic Supplementary Information The online version contains supplementary material available at 10.1007/s13555-022-00850-7.

show abstract

Topical ruxolitinib 1.5% (JAK1/JAK2 inhibitor) improves clinical and patient‐reported outcomes in moderate to severe chronic hand dermatitis: Data from a small open‐label trial

Smith,

Lally,

Moy

et al. 2024

JEADV Clinical Practice

View full text Add to dashboard Cite

BackgroundChronic hand dermatitis (CHD) has suboptimal treatments and a negative impact on quality of life (QoL). Topical ruxolitinib, a JAK1/JAK2 inhibitor, is approved for vitiligo and mild‐to‐moderate atopic dermatitis, but has not previously been studied specifically for CHD.ObjectivesEvaluate the impact of ruxolitinib in CHD.MethodsA 12‐week, investigator‐initiated, open‐label trial evaluated ruxolitinib 1.5% in 15 adults with recalcitrant moderate‐to‐severe CHD. Primary outcomes included the proportion of patients: (1) achieving an Investigator Global Assessment (IGA) treatment success (0 or 1 score with a two‐step improvement) (2) a Hand Eczema Severity Index (HECSI)‐75 improvement at 12 weeks. Additional outcomes: clinical improvement at 4 and 8 weeks, improvement in itch (Numerical Rating Scale [NRS]) and QoL outcomes (i.e., Dermatology Life Quality Index [DLQI] and Skindex‐Mini).ResultsAt 12 weeks, 13/15 participants (86%) achieved a HECSI‐75, 12/15 participants (80%) had a two‐point reduction in IGA and 8/15 participants (53%) achieved an IGA treatment success. Both atopic dermatitis (AD; n = 7) and non‐AD (n = 8) CHD participants had clinical improvement in HECSI at 12 weeks (p < 0.01). 10/12 participants with baseline NRS ≥ 2 (83%) achieved a ≥ 2 point reduction on average itch at 12 weeks. 9/10 with baseline NRS ≥ 4 (90%) achieved a ≥4‐point itch reduction by 4 and 12 weeks. A significant decline in self‐reported daily itch (average and worst) was observed within the first week of treatment (p < 0.001). By CHD subtype, AD‐CHD had greater itch at baseline compared to non‐AD CHD (p < 0.01), consequently itch reduction was greater in AD‐subtype. Improvement in QoL (DLQI, Skindex‐Mini) was achieved at 4 weeks maintained to 12 weeks (p < 0.01). No treatment‐related adverse events were reported during the study and no rescue medications were used.ConclusionsRuxolitinib may be a promising treatment for CHD, improving clinical outcomes, itch and QoL. Significant improvement was achieved at 4 weeks and maintained through 12 weeks of treatment.

show abstract

Three-question Skindex-Mini measures quality of life in children with atopic dermatitis

Cited by 4 publications

References 5 publications

Measurement properties of quality‐of‐life outcome measures for children and adults with eczema: A systematic review update 2.0

Measurement properties of quality‐of‐life outcome measures for children and adults with eczema: A systematic review update 2.0

Similarities and Differences in the Perception of Atopic Dermatitis Burden Between Patients, Caregivers, and Independent Physicians (AD-GAP Survey)

Topical ruxolitinib 1.5% (JAK1/JAK2 inhibitor) improves clinical and patient‐reported outcomes in moderate to severe chronic hand dermatitis: Data from a small open‐label trial

Contact Info

Product

Resources

About